Rapid decay of anti-SARS-CoV-2 antibodies in infection-naïve healthcare workers four months after vaccination

Stamatopoulou, Maria; Tsamadias, Vasileios; Theodosopoulos, Theodosios; Demeridou, Stiliani; Kaparos, George; Memos, Nikolaos; Konstadoulakis, Manoussos M.; Baka, Stavroula

doi:10.18683/germs.2021.1300

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brisotto et al showed a significant antibody decay independent of age and sex in a cohort of 767 healthcare workers 4 months after two-dose vaccination 20 . Similarly, Stamatopoulou et al, in a cohort of 142 infection-naïve healthcare workers, found that the total mean of anti-SARS-CoV-2 IgG levels decreased significantly four months following the second dose 21 . Also, Malipiero et al 22 and Matusali et al 23 , in health care workers who underwent COVID-19 vaccination, showed a marked decline in anti-RBD-IgG levels at six months.…”

Section: Discussionmentioning

confidence: 82%

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Sasso

Agnello

Giglio

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Immunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the long immunity against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. The aim of this study was to evaluate the kinetics of antibody response in vaccine recipients. We measured anti-S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 1013 healthy individuals naïve to SARS-CoV2 infection after two and three COVID-19 vaccine doses. We found that anti-S-RBD IgG levels are higher in females than males. Antibody levels gradually decrease to a steady state after four months since the peak, and the decay is independent of age, sex, vaccine doses, and baseline antibodies titer. The third dose induces a high anti-S-RBD IgG reactivity in individuals with previous high responses and triggers a moderate-high anti-S-RBD IgG reactivity. The assessment of anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third SARS-CoV-2 vaccine dose is associated with a significant immunological response. Thus, our results support the efficacy of the vaccine programs and the usefulness of the third dose.

show abstract

Section: Discussionmentioning

confidence: 82%

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Sasso

Agnello

Giglio

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…According to a prospective study, post-vaccination antibody levels significantly increase after the second dose of the BNT162b2 mRNA COVID-19 vaccine, followed by a significant and rapid decay of anti-SARS-CoV-2 antibodies in infection-naïve healthcare workers four months after vaccination, suggesting that the vaccine offers little protection against the new variants. 86 Vaccination with two homologous BNT162b2 or ChAdOx1 doses provides no or limited protection against the Omicron variant. Neutralizing titers on sera from homologous ChAdOx1 dropped to below the detectable level, while neutralizing titers on sera from homologous BNT162b2 were above the detection threshold but reduced by 29.8-fold.…”

Section: Negative Impacts Of Omicron Sars‐cov‐2 Variantmentioning

confidence: 99%

Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection

Abebe¹,

G/Medhin²,

T/Mariam³

et al. 2022

IDR

View full text Add to dashboard Cite

Since the emergence of COVID 19, the authentic SARS-CoV-2 has evolved into a range of novel variants that are of more global concern. In late November 2021, the Omicron (lineage B.1.1.529) variant was identified as a new variant and considered as the fifth variant of concern. Omicron harbors a genetic profile that is exceedingly unusual, with a huge number of mutations. Above thirty mutations are localized in the S protein, while some are found in other structural and non-structural proteins. Half of the mutations in the S protein are in the RBD, which is a major target of antibodies, showing that Omicron mutations may affect antibody binding affinity to the S protein. The Omicron variant has been found to result in immune escape, therapeutic or vaccine escape, as well as increased transmissibility and reinfection risk, explaining its rapid international spread that sparks a global alarm even more serious than the previously reported variants. Omicron has the capability to bypass at least some of the multi-faceted immune responses induced by prior infection or vaccination. It is shown to extensively escape neutralizing antibodies while evading cell mediated immune defense to a lesser extent. The efficacy of COVID 19 vaccines against Omicron variant is decreased with primary vaccination, showing that the vaccine is less efficient in preventing Omicron infections. However, after receiving a booster vaccine dose, the immunological response to Omicron significantly improved and hold promising results. Despite the mild nature of the disease in most vaccinated people, the rapid spread of Omicron, as well as the increased risk of re-infection, poses yet another major public health concern. Therefore, effort should be devoted to maintaining the existing COVID 19 preventive measures as well as developing new vaccination strategies in order to control the fast dissemination of Omicron.

show abstract

Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection

Flor,

García,

Molineri

et al. 2023

Vaccine

View full text Add to dashboard Cite

Rapid decay of anti-SARS-CoV-2 antibodies in infection-naïve healthcare workers four months after vaccination

Cited by 4 publications

References 0 publications

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection

Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection

Contact Info

Product

Resources

About